Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Severson

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Results and Problems in Cell Differentiation|July 8, 2009
T-cells in multiple sclerosisChristopher Severson, David A Hafler
Multiple Sclerosis and Related Disorders|June 16, 2022
COVID-19 severity is associated with worsened neurological outcomes in multiple sclerosis and related disordersSarah E Conway, Brian C Healy, Jonathan Zurawski, et al.
The International Journal of Neuroscience|January 20, 2017
Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosisGloria Kim, Renxin Chu, Fawad Yousuf, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 18, 2020
Prospective growth and developmental outcomes in infants born to mothers with multiple sclerosisTatenda Dawn Mahlanza, Maria Claudia Manieri, Eric C Klawiter, et al.
Neurology. Clinical Practice|January 15, 2025
A Real-World Prospective Multiple Sclerosis Pregnancy Registry in the United States: PREG-MSMaria K Houtchens, Maria Claudia Manieri, Tatenda Dawn Mahlanza, et al.
Neuroreport|August 8, 2014
An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2Rohit Bakshi, Mohit Neema, Shahamat Tauhid, et al.
Multiple Sclerosis and Related Disorders|August 11, 2022
Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomesKathryn B Holroyd, Brian C Healy, Sarah Conway, et al.
Plos Genetics|January 3, 2009
IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor productionLisa M Maier, Christopher E Lowe, Jason Cooper, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|April 14, 2023
Preserved T cell but attenuated antibody response in MS patients on fingolimod and ocrelizumab following 2nd and 3rd SARS-CoV-2 mRNA vaccineSarah Conway, Shrishti Saxena, Clare Baecher-Allan, et al.
Contemporary Clinical Trials|August 14, 2016
Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosisRobert J Fox, Christopher S Coffey, Merit E Cudkowicz, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Results and Problems in Cell Differentiation|July 8, 2009
T-cells in multiple sclerosisChristopher Severson, David A Hafler
Multiple Sclerosis and Related Disorders|June 16, 2022
COVID-19 severity is associated with worsened neurological outcomes in multiple sclerosis and related disordersSarah E Conway, Brian C Healy, Jonathan Zurawski, et al.
The International Journal of Neuroscience|January 20, 2017
Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosisGloria Kim, Renxin Chu, Fawad Yousuf, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 18, 2020
Prospective growth and developmental outcomes in infants born to mothers with multiple sclerosisTatenda Dawn Mahlanza, Maria Claudia Manieri, Eric C Klawiter, et al.
Neurology. Clinical Practice|January 15, 2025
A Real-World Prospective Multiple Sclerosis Pregnancy Registry in the United States: PREG-MSMaria K Houtchens, Maria Claudia Manieri, Tatenda Dawn Mahlanza, et al.
Neuroreport|August 8, 2014
An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2Rohit Bakshi, Mohit Neema, Shahamat Tauhid, et al.
Multiple Sclerosis and Related Disorders|August 11, 2022
Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomesKathryn B Holroyd, Brian C Healy, Sarah Conway, et al.
Plos Genetics|January 3, 2009
IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor productionLisa M Maier, Christopher E Lowe, Jason Cooper, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|April 14, 2023
Preserved T cell but attenuated antibody response in MS patients on fingolimod and ocrelizumab following 2nd and 3rd SARS-CoV-2 mRNA vaccineSarah Conway, Shrishti Saxena, Clare Baecher-Allan, et al.
Contemporary Clinical Trials|August 14, 2016
Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosisRobert J Fox, Christopher S Coffey, Merit E Cudkowicz, et al.
Pageof 2